Firebrick Pharma Limited (AU:FRE)
ASX:FRE
Want to see AU:FRE full AI Analyst Report?
FRE Stock Chart & Stats
AU$0.05
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.05
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.09
Previous CloseN/A
Volume87.61K
Average Volume (3M)91.61K
Market Cap
AU$10.41M
Enterprise ValueAU$7.89M
Total Cash (Recent Filing)AU$1.44M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta-0.41
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding285,198,970
10 Day Avg. Volume136,612
30 Day Avg. Volume91,607
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)8.38
Price to Sales (P/S)44.43
P/FCF Ratio-7.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA zero-debt capital structure materially reduces financial distress risk and preserves flexibility to fund R&D or trials via equity or partnerships. Over a 2–6 month horizon this lowers mandatory cash outflows, supporting survival while management pursues commercialization or financing options.
Improving Cash Burn TrendA meaningful reduction in cash burn indicates management has tightened operations or optimized spending. While cash flow remains negative, an improving trend increases runway and the probability the company can reach value-inflection events or secure financing on better terms over coming months.
Positive Gross MarginA ~36% gross margin shows the core product or offering can generate unit-level profit. If fixed costs and operating expenses are controlled or revenues recover, this structural margin provides a pathway to operating leverage and eventual profitability as scale returns.
Bears Say
Severe Revenue DeclineA ~74% year-on-year revenue collapse signals lost customers, product access or market traction and undermines scalability. Such a steep, structural downturn makes recovery harder: fixed costs absorb a larger share of shrinking revenue, prolonging the time to self-sustaining operations.
Deep Negative ProfitabilityExtremely negative net margins reflect outsized operating losses relative to revenue, indicating current business economics are unsustainable without material revenue recovery or cost reduction. Persistent losses will pressure equity, limit strategic options, and raise refinancing needs.
Consistent Negative Cash FlowOngoing negative operating and free cash flows show the company cannot self-fund operations and must rely on external capital. Over months this consumes cash reserves, increases dilution risk when raising funds, and constrains investment in development or commercialization activities.
Firebrick Pharma Limited News
FRE FAQ
What was Firebrick Pharma Limited’s price range in the past 12 months?
Firebrick Pharma Limited lowest share price was AU$0.03 and its highest was AU$0.09 in the past 12 months.
What is Firebrick Pharma Limited’s market cap?
Firebrick Pharma Limited’s market cap is AU$10.41M.
When is Firebrick Pharma Limited’s upcoming earnings report date?
Firebrick Pharma Limited’s upcoming earnings report date is Aug 28, 2026 which is in 64 days.
How were Firebrick Pharma Limited’s earnings last quarter?
Firebrick Pharma Limited released its earnings results on Mar 04, 2026. The company reported -AU$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.005.
Is Firebrick Pharma Limited overvalued?
According to Wall Street analysts Firebrick Pharma Limited’s price is currently Overvalued.
Does Firebrick Pharma Limited pay dividends?
Firebrick Pharma Limited does not currently pay dividends.
What is Firebrick Pharma Limited’s EPS estimate?
Firebrick Pharma Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Firebrick Pharma Limited have?
Firebrick Pharma Limited has 285,198,970 shares outstanding.
What happened to Firebrick Pharma Limited’s price movement after its last earnings report?
Firebrick Pharma Limited reported an EPS of -AU$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.407%.
Which hedge fund is a major shareholder of Firebrick Pharma Limited?
Currently, no hedge funds are holding shares in AU:FRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Firebrick Pharma Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:FRE Sentiment 90%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$14.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
11.66%
12-Months-Change
Fundamentals
Return on Equity
-140.26%
Trailing 12-Months
Asset Growth
24.27%
Trailing 12-Months
Company Description
Firebrick Pharma Limited
Firebrick Pharma Limited, an enterprise established in 2012 and headquartered in Melbourne, Australia, is dedicated to the research, development, and market launch of Nasodine, a nasal spray treatment for the common cold, exclusively for the Australian market.
Technical Analysis
Hexima Ltd
―
Botanix Pharmaceuticals Limited
―
Recce Pharmaceuticals Ltd.
―
Arovella Therapeutics Limited
―
Inoviq Ltd
―
Options Prices
Currently, No data available
---